Integra LifeSciences (NASDAQ:IART) Shares Down 4.4% – Should You Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART) traded down 4.4% on Monday . The stock traded as low as $21.61 and last traded at $22.15. 303,470 shares changed hands during trading, a decline of 11% from the average session volume of 341,422 shares. The stock had previously closed at $23.17.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Truist Financial decreased their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Citigroup raised their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Finally, Bank of America decreased their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Trading Up 0.5 %

The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -247.19, a P/E/G ratio of 0.82 and a beta of 1.16. The business has a 50-day moving average of $23.32 and a two-hundred day moving average of $22.77.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the business posted $0.76 earnings per share. Research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds have recently made changes to their positions in IART. KBC Group NV boosted its stake in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in Integra LifeSciences during the 3rd quarter worth about $73,000. Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences during the 2nd quarter worth about $114,000. Centiva Capital LP acquired a new stake in Integra LifeSciences in the 3rd quarter valued at about $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Integra LifeSciences in the third quarter worth about $198,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.